These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Elyasi S; Shojaee FSR; Allahyari A; Karimi G Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153 [TBL] [Abstract][Full Text] [Related]
8. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Ebrahimpour Koujan S; Gargari BP; Mobasseri M; Valizadeh H; Asghari-Jafarabadi M Phytomedicine; 2015 Feb; 22(2):290-6. PubMed ID: 25765835 [TBL] [Abstract][Full Text] [Related]
9. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study. Gadisa DA; Assefa M; Wang SH; Yimer G J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial. de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial. Asgarshirazi M; Shariat M; Sheikh M Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):296-302. PubMed ID: 28603098 [TBL] [Abstract][Full Text] [Related]
14. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362 [TBL] [Abstract][Full Text] [Related]
15. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758 [TBL] [Abstract][Full Text] [Related]
16. Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial. Malta CEN; Carlos ACAM; de Alencar MCM; Alves E Silva EF; Nogueira VBC; Alves APNN; Chaves FF; de Moura JFB; de Barros Silva PG Support Care Cancer; 2022 Mar; 30(3):2569-2580. PubMed ID: 34799776 [TBL] [Abstract][Full Text] [Related]
17. Can we consider silymarin as a treatment option for vitiligo? A double-blind controlled randomized clinical trial of phototherapy plus oral Jowkar F; Godarzi H; Parvizi MM J Dermatolog Treat; 2020 May; 31(3):256-260. PubMed ID: 30935260 [No Abstract] [Full Text] [Related]
18. The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study. Serageldin MA; Kassem AB; El-Kerm Y; Helmy MW; El-Mas MM; El-Bassiouny NA Drug Saf; 2023 Jun; 46(6):587-599. PubMed ID: 37131014 [TBL] [Abstract][Full Text] [Related]
19. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. Luangchosiri C; Thakkinstian A; Chitphuk S; Stitchantrakul W; Petraksa S; Sobhonslidsuk A BMC Complement Altern Med; 2015 Sep; 15():334. PubMed ID: 26400476 [TBL] [Abstract][Full Text] [Related]
20. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial. Jin Y; Wang X; Chen K; Chen Y; Zhou L; Zeng Y; Zhou Y; Pan Z; Wang D; Li Z; Liang Y; Ling W; Li D Lipids Health Dis; 2024 Aug; 23(1):239. PubMed ID: 39097726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]